Clinical Trials

290 enrolled

Multiple Myeloma

NCT04722146 2026-03-13

MajesTEC-2

140 enrolled

Multiple Myeloma

NCT05050097 2026-03-13

MonumenTAL-2

166 enrolled

Multiple Myeloma

NCT06768489 2026-03-13

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Phase 1 Recruiting

140 enrolled

Multiple Myeloma

NCT03984097 2026-03-10

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

50 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05556798 2026-02-24

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

9 enrolled

Multiple Myeloma

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

125 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05556616 2026-01-29

iinnovate-2

15 enrolled 15 charts

Multiple Myeloma

NCT05137054 2026-01-22

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Phase 1 Recruiting

317 enrolled

Multiple Myeloma

NCT04910568 2025-12-24

CAMMA 1

126 enrolled

Multiple Myeloma

NCT05259839 2025-12-19

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

283 enrolled

Multiple Myeloma, Neoplasms

NCT03287908 2025-10-08

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

174 enrolled

Multiple Myeloma, Neoplasms

NCT04045795 2025-09-12

Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

56 enrolled

Multiple Myeloma

NCT03828292 2025-08-19

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

15 enrolled 91 charts

Multiple Myeloma

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

240 enrolled 2 FDA

Multiple Myeloma

NCT04667663 2025-01-09

CPD-DARA

16 enrolled

Multiple Myeloma

NCT02616640 2024-09-19

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

114 enrolled

Multiple Myeloma, Recurrence

NCT02400242 2024-07-09

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

85 enrolled

Multiple Myeloma

NCT03143985 2024-05-24

Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

18 enrolled

Multiple Myeloma

NCT01728259 2023-05-09

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

18 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT04895410 2023-03-06

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

8 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT01575925 2022-11-04

POM Renal

25 enrolled

Multiple Myeloma, Renal Insufficiency

NCT02283775 2021-07-09

PomdeSAR

54 enrolled

Multiple Myeloma

NCT02569320 2021-06-15

HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

9 enrolled

Multiple Myeloma

NCT01999335 2021-04-27

A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma

33 enrolled 21 charts

Multiple Myeloma

NCT02431208 2021-04-02

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

85 enrolled

Multiple Myeloma

NCT04355039 2020-08-19

INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Phase 1 Withdrawn

Multiple Myeloma

NCT01497093 2020-04-07

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

34 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT03015922 2020-01-22

MUKeleven

Phase 1 Unknown

4 enrolled

Multiple Myeloma

NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

16 enrolled

Disease, Multiple Myeloma, Recurrence, Disease Progression

NCT03657420 2019-08-14

Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Phase 1 Withdrawn

Multiple Myeloma

NCT02462525 2018-09-13

Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

74 enrolled

Multiple Myeloma

NCT02071888 2018-07-18

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

25 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT03424928 2018-02-07

A Pilot Bioequivalence Study of Pomalidomide

12 enrolled

Multiple Myeloma

NCT02103335 2017-11-22

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

38 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01807286 2016-05-13

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

3 enrolled

Amyloidosis, Neoplasms, Plasma Cell

NCT01889420 2015-07-31

Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

1 enrolled 3 charts